Action4Diabetes (A4D) and the Myanmar Society of Endocrinology & Metabolism (MSEM) have signed a memorandum of understanding (MoU) for the establishment of the Myanmar Type 1 Diabetes (T1D) Task Force with the aim to improve access to quality T1D care in the country.
The MSEM is a professional organisation established in Myanmar whose aim is to advance excellence in endocrinology and diabetes by promoting education, medical practice and research to the benefit of the Burmese.
The establishment of this Myanmar T1D Task Force illustrates the consistent dedication among A4D, MSEM and relevant stakeholders like Novo Nordisk – Changing Diabetes in Children (CDiC) in developing sustainable and locally owned solutions to continuously improve health outcomes and quality of life for people with T1D in Myanmar.
The partnership will focus on the following areas of collaboration to drive change and sustainable impact at both a national and local level.
Provide free access to essential medical supplies for economically disadvantaged young people with T1D, ensuring optimal support during the transition of care from paediatric to adult care
Improve patient empowerment and family support through ongoing T1D education and peer support initiatives using HelloType1, an online education platform available in local languages
Develop epidemiology data set to establish insights and clinical and quality of life measures in order to deliver improved health outcomes
Strengthen local healthcare capacity for improved diagnosis and management of T1D
The partnership will remain in effect for three years, from October 2022 until December 2025. A4D and MSEM will aim to provide essential medical support to >650 young people with T1D across Myanmar and engage with >2000 online T1D Community members on the HelloType1 platform by the end of 2025.
We are confident that working together will enable us to have a real impact on the ground and create lasting change for people with Type 1 Diabetes in the country.